0 Replies
... Attractively priced as the street transitions from ascribing value to rnai companies based on partnership deals and moves to appreciating upcoming proof of concept data (poc) that could reignite large pharma ... Contine Reading & Discuss→
0 Replies
BOULDER, Colo. and FRANKFURT, Germany, November 30, 2010 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, and t2cure, a clinical stage biopharmaceutical company developing progenitor cell-based regenerative therapeutics for cardiac or peripheral vascular diseases, announced... Contine Reading & Discuss→
0 Replies
Stories include:
Special Report: Top 5 Game-Changing Drug Delivery Technologies. Report
U.S. and European patents have been issued for Tekmira Pharmaceuticals' RNAi drug delivery technology. Report Contine Reading & Discuss→
0 Replies
Stories include:
Roche is dumping another development pact. This time the Swiss pharma giant is dropping a deal to develop new hepatitis C drugs with Ligand Pharmaceuticals ($LGNDD), according to the UK biotech.
The two companies struck a deal back in 2008 to use Metabasis' liver-targeting technology to find a... Contine Reading & Discuss→
0 Replies
Stories include:
In the wake of Roche's stunning decision to write off its $500 million investment in RNAi work, some of the analysts who cover companies in the field appear to be losing confidence in what once was widely viewed as one of the most compelling new development categories since... Contine Reading & Discuss→
0 Replies
Stories include:
FierceBiotech is the biotech industry's daily monitor, with a special focus on drug discovery and clinical trials. Keep up to speed with the latest biotechnology trends, breakthroughs and FDA approval news. Join 90,000+ biotechnology and pharma industry professionals who get FierceBiotech via daily email. Sign up today!
About... Contine Reading & Discuss→
0 Replies
Stories include:
As FierceBiotech reported yesterday, Roche singled out its work in RNAi when choosing its R&D targets for the budget axe, announcing plans to shutter the work underway in Kulmbach, Germany, Nutley, NJ and Madison, WI. That may not be a major cutback in the broad scope of the... Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., Nov 15, 2010 (BUSINESS WIRE) – RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the third quarter ended September 30, 2010. Contine Reading & Discuss→
